Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

NCT03770728 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03770728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03770728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
August 1, 2019
Completion date
December 27, 2020
Enrollment
312 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus